Modifying phase i methodology to facilitate enrolment of molecularly selected patients

European Journal of Cancer

Volumn 49, Issue 7, 2013, Pages 1515-1520

  Hollebecque, Antoine ^a   Postel Vinay, Sophie ^a   Verweij, Jaap ^b   Demetri, George D ^c   Flaherty, Keith ^d   Bedard, Philippe ^e   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Clinical trials; Drug development; Phase I studies; Trial methodology

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; CREATININE; CRIZOTINIB; OLAPARIB; OXALIPLATIN; VEMURAFENIB; VISMODEGIB;

ADVANCED CANCER; ARTICLE; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MELANOMA; METHODOLOGY; NEUROPATHY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG THERAPY; HUMANS; NEOPLASMS; PATIENT SELECTION; RESEARCH DESIGN;

EID: 84876150236     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.12.012     Document Type: Article

References (27)

1. T.A. Yap, S.K. Sandhu, P. Workman, and J.S. De Bono Envisioning the future of early anticancer drug development Nat Rev Cancer 10 7 2010 514 523
2. J.S. De Bono, and A. Ashworth Translating cancer research into targeted therapeutics Nature 467 7315 2010 543 549
3. C.P. Carden, D. Sarker, and S. Postel-Vinay Drug Discov Today 15 3-4 2010 88 97
4. M.E. Gutierrez, S. Kummar, and G. Giaccone Next generation oncology drug development: opportunities and challenges Nat Rev Clin Oncol 6 5 2009 259 265
5. A.T. Van Oosterom, I. Judson, and J. Verweij Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 9291 2001 1421 1423 (Pubitemid 33055745)
6. E.L. Kwak, Y.-J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 18 2010 1693 1703
7. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
8. D.D. Von Hoff, J.J. Stephenson, and P. Rosen Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers J Clin Oncol 28 33 2010 4877 4883
9. A.M. Tsimberidou, N.G. Iskander, and D.S. Hong Personalized medicine in a phase I clinical trials program: the MD Anderson cancer center initiative Clin Cancer Res 18 22 2012 6373 6383
10. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 2009 123 134
11. J. Verweij, M. De Jonge, F. Eskens, and S. Sleijfer Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design Mol Oncol 6 2 2012 196 203
12. D. Olmos, R.P. A'hern, and S. Marsoni Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors J Clin Oncol 30 9 2012 996 1004
13. J. Verweij "No risk, no fun": challenges for the oncology phase I clinical trial time-performance Eur J Cancer 44 17 2008 2600 2607
14. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 8 2012 707 714
15. M.-S. Tsao, A. Sakurada, and J.-C. Cutz Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 2 2005 133 144 (Pubitemid 41058345)
16. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2 2005 123 132 (Pubitemid 41058344)
17. L.V. Sequist, B.A. Waltman, and D. Dias-Santagata Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 75 2011 75ra26
18. W.M. Michels, D.C. Grootendorst, M. Verduijn, E.G. Elliott, F.W. Dekker, and R.T. Krediet Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size Clin J Am Soc Nephrol 5 6 2010 1003 1009
19. P.S. Kamath, R.H. Wiesner, and M. Malinchoc A model to predict survival in patients with end-stage liver disease Hepatology 33 2 2001 464 470 (Pubitemid 32119037)
20. M. García-Cortés, M.I. Lucena, K. Pachkoria, Y. Borraz, R. Hidalgo, and R.J. Andrade Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury Aliment Pharmacol Ther 27 9 2008 780 789 (Pubitemid 351490076)
21. G.P. Aithal, M.D. Rawlins, and C.P. Day Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions J Hepatol 33 6 2000 949 952
22. V.A. Maria, and R.M. Victorino Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis Hepatology 26 3 1997 664 669 (Pubitemid 27392358)
23. R.K. Verbeeck Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction Eur J Clin Pharmacol 64 12 2008 1147 1161
24. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134 (Pubitemid 46089673)
25. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 2008 378 390
26. A.-L. Cheng, Y.-K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 1 2009 25 34
27. A.M. Tsimberidou, K. Letourneau, and S. Wen Phase I clinical trial outcomes in 93 patients with brain metastases: the MD Anderson cancer center experience Clin Cancer Res 17 12 2011 4110 4118